244 related articles for article (PubMed ID: 33566300)
21. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
22. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
24. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
[TBL] [Abstract][Full Text] [Related]
25. Clinical Outcomes of Patients with Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era.
Wang Y; Li J; Liu T; Ge M; Ji X; Chu Z; Zhan Q; Liang X; Zhou X
World Neurosurg; 2023 Feb; 170():e500-e509. PubMed ID: 36396052
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report.
Ma Y; Liu H; Zhang M; Liu B; Ding Q; Zhang L; Guo L; Liu M
Ann Palliat Med; 2022 Apr; 11(4):1533-1541. PubMed ID: 34263612
[TBL] [Abstract][Full Text] [Related]
27. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
Ge M; Zhan Q; Zhang Z; Ji X; Zhou X; Huang R; Liang X
BMC Cancer; 2019 Feb; 19(1):143. PubMed ID: 30755180
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of Clinicopathological Feature and Prognosis for
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
[TBL] [Abstract][Full Text] [Related]
30. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
[TBL] [Abstract][Full Text] [Related]
31. [Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].
Lin Y; Li H; Huang M; Yin Z; Wu J
Zhongguo Fei Ai Za Zhi; 2020 Jun; 23(6):516-525. PubMed ID: 32517459
[TBL] [Abstract][Full Text] [Related]
32. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
Nakagawa K; Takano K; Nishino K; Ohe S; Nakayama T; Arita H
J Neurooncol; 2024 May; 167(3):397-406. PubMed ID: 38430420
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
[TBL] [Abstract][Full Text] [Related]
35. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.
Li H; Lin Y; Yu T; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
Ann Palliat Med; 2020 Jul; 9(4):2341-2346. PubMed ID: 32648459
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.
Wu X; Xing P; Shi M; Guo W; Zhao F; Zhu H; Xiao J; Wan J; Li J
Front Oncol; 2022; 12():664420. PubMed ID: 35574310
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
Nosaki K; Yamanaka T; Hamada A; Shiraishi Y; Harada T; Himeji D; Kitazaki T; Ebi N; Shimose T; Seto T; Takenoyama M; Sugio K
Oncologist; 2020 Dec; 25(12):e1869-e1878. PubMed ID: 32654250
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
[TBL] [Abstract][Full Text] [Related]
39. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
40. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
